First Healthy Volunteer Dosed in Symvivo’s Phase 1 Clinical Trial of bacTRL-Spike™, an Oral COVID-19 Vaccine Candidate
BURNABY, British Columbia--(BUSINESS WIRE)--Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, today announced the enrollment...






